ACTRN12614001287628
Not yet recruiting
Phase 2
patients with locally resectable pancreatic cancerrandomized to standard preoperative assessment or additional primovist MRI to further evaluate for liver metastasescomparing 12 month recurrence rate between the 2 groups
jai seema bagia0 sites24 target enrollmentDecember 10, 2014
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- pancreas adenocarcinoma
- Sponsor
- jai seema bagia
- Enrollment
- 24
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Sex: Male and Females
- •Age range: 18\-85
- •Disease status: Locally operable pancreatic adenocarcinoma diagnosed by CT \+\- elevated tumour markers \+\- cholangiography \+\- cytology.
- •No liver metastases on CT staging.
Exclusion Criteria
- •Patients with significant renal impairment, which precludes them having the CT, contrast or Primovist contrast for the MRI would be excluded.
- •Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
- •Patients with a history of renal disease with an EGFR less than 40\.
- •Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.
- •Patients with devices that exclude them from Primovist MRI will be excluded from the study, in particular, patients with pacemakers and/or implantable devices.
- •Patients unwilling and unable to give written informed consent to participate in the study. Patients unable to understand study information with the help of an interpreter.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Observational study of pancreatic cancer patients with positive peritoneal lavage cytologypancreatic cancerJPRN-UMIN000032477Shizuoka Cancer Center150
Recruiting
Not Applicable
Pancreatic Locally advanced Irresectable Cancer AblatioN (PELICAN trial)Locally advanced pancreatic cancernon-resectabel pancreatic tumor10017998NL-OMON56404Amsterdam UMC174
Terminated
Phase 1
Investigation of gemcitabine combined with temsirolimus, in patients with inoperable or metastatic pancreatic cancer. A phase I-II study by the Hellenic Cooperative Oncology Group with biomarker evaluation (HE3/07)Patients with inoperable or metastatic pancreatic cancerCancer - PancreaticACTRN12611000643976Hellenic Cooperative Oncology Group85
Active, not recruiting
Phase 1
A study in patients with borderline unresectable pancreatic cancer, where Abraxane and Gemcitabine will be administered with the goal of shrinking tumours to make them operable.ocally advanced pancreatic cancerMedDRA version: 17.0 Level: LLT Classification code 10033606 Term: Pancreatic cancer non-resectable System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-004200-19-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge9
Recruiting
Phase 2
PANcreatic Cancer lOcalized disease in frail or elderly patients unfit for both chemotherapy and surgery treated with Stereotactic Ablative Radiotherapy (PANCOSAR): a multicenter randomized controlled trialNL-OMON52822Vrije Universiteit Medisch Centrum98